Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Enterprise Case Studies

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>

29 October 2012: UCL rides the CREST of a wave with ‘Darwinian’ testing methods

Evolutionary ideas have proved revolutionary at UCL’s Centre for Research on Evolution, Search and Testing (CREST), where its director, Mark Harman, has been working with nature-based algorithms for testing software for more than a decade. More...

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>